Ready to take charge of your clinical data?
Schedule a demo and/or speak to an eClinical Solutions representative to learn more.
The development of Vibegron—a treatment of overactive bladder (OAB) condition in adults—began in 2017. Urovant Sciences acquired the Vibegron assets midway through its development process including numerous legacy data sets and an ongoing Phase III study. To achieve the ambitious regulatory submission timeline, the development team needed to partner with an experienced clinical data and statistical programming provider. Working with eClinical Solutions on the regulatory submissions and using the elluminate® Clinical Data Cloud as a centralized data repository, Urovant was able to achieve their submission timelines stretch goals that resulted in an approval for Gemtesa.
Urovant needed to to prepare 17 legacy studies for submission and align them with ongoing studies, which required them to be converted to SDS, the creation of the TS trial summary domain, the SDTM annotated CRF, and a defined PDF. Since the TS domain requires deep understanding of the parameters of the study, creating these sets was challenging. Urovant was also working with multiple vendors on the studies and needed a final statistical analytics plan that aligned across these studies.
To meet these goals and be prepared for submission, Urovant needed a team with a proven track record of submission experience, and the ability to deliver quality results on time. The project required expert statistical and programming support, knowledge of CDISC standards, and the ability to be flexible in the face of challenges. Urovant turned to eClinical Solutions, taking advantage of their expert clinical programming team and lead statisticians.
As soon as data became standardized and available from the legacy studies, the eClinical team performed an inventory and gap analysis of the data and documentation that existed. This allowed for Urovant and eClinical to identify issues early on. With individual studies being run by other vendors, they performed submission package dry runs as data was received which allowed them to notice issues up front and fix them quickly and gave the joint team extra time to review data and the medical writing team more time for additional requests. With these processes in place, they were able to meet their timelines.
The ISS package that eClinical and Urovant collaborated on included:
Along with a well-documented and well-defined plan, eClinical’s experienced biostatistics team created an efficient and successful submissions process to gain approval for Urovant Gemtesa.
Urovant Sciences was able to achieve a submission-ready package within an ambitious 8-month timeframe by leveraging the centralized data repository of the elluminate Clinical Data Cloud.
All your trial data from every source, one place for integrated review- listings, patient profiles, analytics, queries and issue management.
Comprehensive visualizations and reporting that support safety and efficacy decisions within and across trials, operational analytics that help proactively manage your trial.
The project required expert statistical and programming support, and eClinical’s Clinical Data Services team helped implement a well-documented and well-defined plan that put Urovant on the path to submissions success.
Tech-enabled approach to shorten submission timelines and improved ability to support real-time creation of “submission ready” datasets
Experienced biostatisticians and SAS programmers provide strategic statistical input and programming to optimize clinical development and ensure regulatory compliance
Denise Shortino
Sr. Director, Biostats, Programming and Data Management
Urovant Sciences
Schedule a demo and/or speak to an eClinical Solutions representative to learn more.